public-health-summit-2018-keynote

5 / 8

Volume 08 Journal of Community Medicine & Health Education Public Health Summit 2018
May 24-25, 2018
Page 16
Notes:
conferenceseries.com
May 24-25, 2018 Osaka, Japan
4th World Congress on
Public Health, Epidemiology & Nutrition
ADHD therapy impact – upon community health from a pediatric endocrine practice perspective
Aprimary goal of pediatricians and especially pediatric endocrinologists is to support healthy physical growth and mental
development of children. The National Institute of Mental Health reports one in five (21%) children have diagnosable
mental, emotional or behavioral disorders with attention deficit/hyperactivity (ADHD) most prevalent. A 2010 survey finds
five million US children 3-17 years of age diagnosed ADHD (8%). With appropriate treatment, children with ADHD can
improve short term learning that raises concerns for non-prescribed use such as during college finals and controversy regarding
ADHD therapy addiction and substance abuse epidemic. We identify 225 of our 5-10 y/o patients (~8%) diagnosed and treated
outside our practice for ADHD and review their progress and the ADHD literature for influence upon response to pediatric
endocrine therapy for autoimmune thyroiditis (56 of 225), hyperthyroidism (3), diabetes mellitus type 1 (9), congenital
adrenal hyperplasia (2) and the majority for various physical growth disorders (180). We present two case reports where
ADHD consideration delayed endocrine diagnoses, but we note ADHD therapy to minimally interfere with thyroid, diabetes
mellitus or adrenal therapy though individual compliance can be adversely affected. We note short term ADHD therapy
physical growth delay consistent with literature assessment waiting at least 6 year anticipated “catch-up” growth. We encourage
ADHD children to attend to monitoring for appropriate ADHD therapy adjustments with their prescribing physicians. Our
observations support particular attention to 4-6 months interval growth assessments for pubertal children, especially those on
ADHD therapy, to consider early growth therapy to optimize attainment of individual adult height potential.
Biography
George William Moll has received Biochemistry PhD and MD from University of Chicago Pritzker School of Medicine. He is Tenured Professor Pediatrics and
Pediatric Endocrinology at University of Mississippi Medical Center (UMMC) where he has been Division Chair for 25 years. He published over 50 peer reviewed
papers and 100 abstracts. He has over 40 years Clinical practice, Education as Graduate Faculty UMMC School of Medicine and Research experience. He is
UMMC Sigma XI Chapter President and holds Chair or Vice-Chair in Mississippi Academy of Sciences Division of Health Sciences. He serves as abstract and
Journal Reviewer and Mississippi Health Department Genetics Advisory Board member.
George WilliamMoll
University of Mississippi Medical Center, USA
George William Moll, J Community Med Health Educ 2018, Volume 8
DOI: 10.4172/2161-0711-C2-034